- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00716456
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
A Phase I/II Trial of Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
The purpose of this study is to test if cetuximab (Erbitux) can shrink lung cancers that initially became smaller after taking erlotinib and then started to get bigger despite continuing treatment. Cetuximab is a medicine approved by the U.S. Food and Drug administration for treatment of head and neck and colon cancer. The goal of the phase I portion of this trial is to find out the highest dose of cetuximab that can be taken together with erlotinib. This study will also give an idea of how well cetuximab shrinks lung cancer when given with erlotinib.
The purpose of this study is to test if cetuximab (Erbitux) can shrink lung cancers that initially became smaller after taking erlotinib or gefitinib and then started to get bigger despite continuing treatment. Cetuximab is a medicine approved by the U.S. Food and Drug administration for treatment of head and neck and colon cancer. The goal of this phase is to determine if cetuximab given with erlotinib causes lung cancers to shrink in size.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States
- Memoral Sloan Kettering Cancer Center
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan-Kettering Cancer Center @ Suffolk
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
Rockville Centre, New York, United States, 11570
- Memorial Sloan-Kettering Cancer Center at Mercy Medical Center
-
Sleepy Hollow, New York, United States, 10591
- Memoral Sloan Kettering Cancer Center at Phelps
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologic evidence of lung adenocarcinoma confirmed at MSKCC
- Measurable (RECIST) indicator lesions not previously irradiated
- Radiographic progression by RECIST during treatment with erlotinib
- Received treatment with erlotinib throughout the one month prior to enrollment
- Received treatment with erlotinib for >3 months
- At least one of the following:
- Previously received treatment with erlotinib, gefitinib, or an investigational EGFR TK inhibitor (patients may have received other treatments subsequently including radiation or chemotherapy) and had a radiographic partial or complete response to treatment as defined by RECIST criteria
- A documented mutation in EGFR exons 19 or 21.
- Karnofsky performance status ≥ or = to 70%
- Total bilirubin: within normal institutional limits. AST/(SGOT)/ALT(SGPT)< or = to 2.5 X institutional upper limit of normal (ULN)
- Signed informed consent
- Effective contraception *
- Age > 18 years old *Sexually active women of childbearing potential must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized. Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control. All WOCBP MUST have a negative pregnancy test within two weeks prior to first receiving investigational product. If the pregnancy test is positive, the patient must not receive investigational product and must not be enrolled in the study. In addition, all WOCBP should be instructed to contact the Investigator immediately if they suspect they might be pregnant (e.g., missed or late menstrual period) at any time during study participation. The Investigator must immediately notify BMS in the event of a confirmed pregnancy in a patient participating in the study.
Exclusion Criteria:
- CNS lesions which are symptomatic and/or requiring escalating doses of corticosteroids.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Prior cetuximab or panitumumab. Prior severe infusion reaction to a monoclonal antibody.
- Current grade 2 or greater skin toxicity on erlotinib therapy
- Radiotherapy ≤ or = to 14 days prior to enrollment
- Any investigational agent or therapy ≤ or = to 30 days before enrollment
- Systemic chemotherapy, hormonal therapy, immunotherapy, or experimental or approved proteins/antibodies (except erlotinib) ≤ or = to 30 days before enrollment
- Women who are pregnant or lactating.
- Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
- Major surgery within 28 days or minor surgery within 14 days of study enrollment
- Men or women of child-bearing potential (women who are post-menopausal < 52 weeks, not surgically sterilized, or not abstinent) not consenting to use adequate contraception (per institutional standard of care) during the course of the study and after the last investigational product(s) administration (24 weeks for women, 4 weeks for men)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
In the phase I portion, patients will be enrolled in cohorts of 3-6 patients;receiving daily erlotinib 100 mg along with cetuximab given every 2 weeks beginning at 250mg/m2 IV.
Following the initial dose, for dose levels 1 and 2 (250 mg/m2 and 375 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 60 minutes.
For dose level 3 (500 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 120 minutes.
The infusion rate of cetuximab should never exceed 10 mg/minute (5 mL/min).
The dose may subsequently be reduced for individual patients, depending on a patient's toxicity.
|
The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose.
Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks.
Patients will have baseline CT, labs and ECG done within 2 weeks of study entry.
Three patients will be enrolled per dose level.
Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter.
Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks.
All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Maximum Tolerated Dose (MTD) of Cetuximab Given Every 2 Weeks
Time Frame: At conclusion of study, up to 24 weeks
|
To determine the maximum tolerated dose (MTD) of cetuximab given every 2 weeks in patients with lung adenocarcinoma receiving erlotinib that have developed acquired resistance to erlotinib (phase I portion)
|
At conclusion of study, up to 24 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gregory Riely, PhD, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Adenocarcinoma
- Adenocarcinoma of Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
- Cetuximab
Other Study ID Numbers
- 08-055
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Adenocarcinoma
-
Hunan Cancer HospitalSuzhou Sheng Diya Biomedical Co., Ltd.Active, not recruitingAdenocarcinoma of the LungChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruitingEGFR Gene Mutation | Lung Adenocarcinoma Stage III | Lung Adenocarcinoma Stage IVChina
-
Rambam Health Care CampusUnknownLung Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Breast Adenocarcinoma
-
Meir Medical CenterUnknownAdenocarcinoma, Bronchiolo-Alveolar | Adenocarcinoma of the LungIsrael
-
Memorial Sloan Kettering Cancer CenterCompletedOligometastatic Lung AdenocarcinomaUnited States
-
Chinese PLA General HospitalUnknown
-
Intergroupe Francophone de Cancerologie ThoraciqueAstraZenecaCompletedPneumonic-type Adenocarcinoma (P-ADC) | Lung Adenocarcinoma With Bronchiolo-alveolar FeatureFrance
-
Wuhan Union Hospital, ChinaRecruitingLung Adenocarcinoma, Stage IChina
-
Fujian Medical University Union HospitalWu Jieping Medical FoundationActive, not recruitingIA Lung Adenocarcinoma | Combined SegmentectomyChina
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedStage IV Lung AdenocarcinomaUnited States
Clinical Trials on erlotinib with cetuximab
-
University of California, DavisNational Cancer Institute (NCI)CompletedLung Cancer | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Eli Lilly and CompanyCompletedNeoplasmsUnited States
-
Regeneron PharmaceuticalsCompleted
-
AbbVie (prior sponsor, Abbott)CompletedAdvanced Solid Tumors
-
M.D. Anderson Cancer CenterCompleted
-
Austin HealthRoyal North Shore Hospital; Ballarat Health Services; Queen Elizabeth Hospital...UnknownMetastatic Colorectal CancerAustralia
-
National Cancer Institute (NCI)CompletedMetastatic Squamous Neck Cancer With Occult Primary | Small Intestine Lymphoma | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer | Gastrointestinal Stromal Tumor | Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Tongue Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer and other conditionsUnited States
-
Hoffmann-La RocheCompleted
-
Shanghai General Hospital, Shanghai Jiao Tong University...UnknownColorectal Cancer Metastatic
-
Universitaire Ziekenhuizen KU LeuvenMerck KGaA, Darmstadt, GermanyCompletedColorectal CancerSpain, France, Belgium, Hungary, Austria